AOD-9604 peptide dose: distinguish oral study amounts from injection claims, and learn why laboratory concentration calculations do not establish a human dose.
There is no validated human subcutaneous AOD-9604 dose to recommend. Repeated online ranges are not clinical standards, and a dose studied by mouth cannot be converted into an injection amount without route-specific evidence. AOD-9604 is not FDA-approved.
What AOD-9604 Is and Why the Dose Is Measured in Micrograms
AOD-9604 is a modified fragment of human growth hormone: hGH residues 177-191 with an added N-terminal tyrosine, making a 16-amino-acid peptide. It is often called HGH fragment 176-191, although it is not the unchanged native sequence.
Micrograms and milligrams are units of mass, not evidence of potency or a dosing interval: 1 mg equals 1000 mcg. The 2024 review did not identify human pharmacokinetic studies, so a claimed 30-minute human subcutaneous half-life cannot justify a daily or split schedule.
AOD-9604 is sold as a research chemical labeled "for laboratory use only," and it is not approved as a drug for weight loss, athletic performance, or any other human condition.
Which Dose Information Comes From Human Research?
The distinction below separates historical oral study doses from unvalidated injection ranges. It should not be used to select a human amount.
| Information type | What was reported | What can be concluded |
|---|---|---|
| Oral obesity research | 0.25, 0.5, or 1 mg daily in the larger trial | Historical trial arms; not recommended injection doses |
| Community injection ranges | Amounts repeated in forums and vendor guides | Repetition does not validate a dose-response relationship |
| Dose escalation | Suggestions to increase an amount when results are absent | No established human subcutaneous titration protocol |
| Five-on/two-off schedules | Planned breaks in community protocols | No validated evidence that this pattern improves safety or benefit |
The oral obesity trial summarized in FDA's 2024 review enrolled 536 participants and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a statistically significant benefit on the primary weight-loss endpoint at 12 weeks. These oral results do not establish an effective subcutaneous dose.
How Often and When to Take AOD 9604
A fasted morning injection has not been shown to outperform fed or later use in the human evidence reviewed in 2024. A proposed mechanism does not establish a required interval before breakfast.
For how often do you take aod 9604, neither split dosing nor weekday-only cycling is established by the reviewed human injection evidence. Human subcutaneous half-life and exposure were not characterized in that review.
The question when to take aod 9604 peptide remains unresolved for human injection. Advice about pre-workout use or exact clock times should not be presented as validated dosing guidance.
How to Use AOD-9604: Injection and Reconstitution Basics
For how to use aod 9604 peptide, separate arithmetic from dosing. A 2 mg amount in a final volume of 2 mL is 1 mg/mL; a hypothetical 250 mcg aliquot is 0.25 mL, or 25 units on a U-100 scale. This calculation does not establish an appropriate human dose.
Diluent, mixing method, concentration, and storage must be compatible with the specific formulation. Generic advice about peptide handling cannot establish stability or suitability for injection.
Why AOD-9604 Gels Up
Reports of aod-9604 gelling up cannot be diagnosed from appearance alone. Formulation, pH, concentration, temperature, and impurities can affect stability, as discussed in the 2024 review.
- Do not add extra diluent or warm a gelled sample as an improvised rescue method.
- Stop using a sample that is cloudy, gelled, or visibly abnormal.
- Check the formulation-specific handling procedure and contact the supplier or responsible laboratory.
- Do not assume a visually clear solution is sterile or chemically intact.
Use storage and beyond-use information established for the particular formulation and container. A generic refrigeration rule or the diluent expiry does not establish the stability of mixed AOD-9604.
AOD 9604 vs MOTS-c: Dosing Differences
AOD-9604 and MOTS-c use different units in online discussions, but that does not validate either schedule. Comparing forum amounts is not a clinical dose comparison.
| Feature | AOD-9604 | MOTS-c |
|---|---|---|
| Origin | Modified growth-hormone fragment | Mitochondrial-derived peptide |
| Human injection amount | Not established by the reviewed AOD-9604 evidence | Do not use community amounts as validated treatment |
| Injection frequency | Not established by the reviewed evidence | A separate investigational question |
| Human subcutaneous half-life | Not established in the 2024 FDA review | Do not infer it from AOD-9604 |
| Research focus | Fat-metabolism mechanisms | Metabolic signaling mechanisms |
| US approval | Not FDA-approved | Not FDA-approved |
The comparison aod 9604 vs mots-c can help distinguish mechanisms and evidence, but it cannot supply an interchangeable dose or schedule.
Safety, Side Effects, and Legal Status
Human obesity studies reviewed by FDA used oral or intravenous administration. Cartilage and osteoarthritis findings discussed in the review included preclinical work; they should not be described as successful human subcutaneous treatment trials.
The adverse-event profile of subcutaneous AOD-9604 was not established by the reviewed human data. Oral or intravenous reports and anecdotal injection complaints must be identified separately.
- Avoid use during pregnancy or breastfeeding.
- Talk with a licensed healthcare professional before using any research peptide.
- Athletes should check current WADA and sport-specific rules, since peptide statuses change over time.
- Never share needles or reuse injection supplies.
Sourcing, Purity, and What to Verify
When evaluating a supplier, purity and documentation matter far more than price. A reputable research vendor provides a batch-specific certificate of analysis from an independent lab showing HPLC purity and mass spectrometry confirmation.
General online marketplaces rarely meet that bar. Listings on large retail sites often carry vague labels, no third-party certificate of analysis, and "not for human use" disclaimers, which makes verifying peptide identity and sterility nearly impossible.
Use storage information validated for the specific formulation rather than assuming all dry powders belong in a freezer and all solutions remain stable in a refrigerator. Do not use a cloudy solution or one with visible particles.
RELATED PEPTIDE TOPICpeptide dosing guideFrequently Asked Questions
What is the typical AOD 9604 peptide dose?
There is no validated human subcutaneous dose in the evidence summarized in FDA's 2024 review. Historical oral trial amounts and ranges repeated in forums do not establish a standard injection amount or titration protocol.
How long does AOD-9604 stay in your system?
A human subcutaneous half-life was not established in the 2024 FDA review, which did not identify human pharmacokinetic studies. A repeated claim of roughly 30 minutes cannot justify a daily or twice-daily injection schedule.
Why does AOD-9604 gel up when it is reconstituted?
Appearance alone cannot establish why a sample gels. Formulation, pH, concentration, temperature, and impurities can affect stability. Do not try to rescue an abnormal sample by improvised warming or extra diluent; use a validated procedure for the specific formulation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.